Tesamorelin

Overview

Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH) distinguished from other peptides in this class by two features: it reproduces the full 44-amino-acid native GHRH sequence rather than a truncated fragment, and it carries a chemical modification — a trans-3-hexenoic acid group attached at the N-terminus — that confers resistance to enzymatic degradation by dipeptidyl-peptidase IV (DPP-IV). This modification was the key innovation that made tesamorelin viable as a once-daily subcutaneous drug rather than a rapidly-degraded research peptide.

The distinction from sermorelin is instructive. Sermorelin corresponds to the active N-terminal 29-residue fragment of GHRH (GHRH 1-29), which retains full receptor-binding activity but is rapidly cleared and was developed principally as a diagnostic and paediatric treatment agent before its 2008 commercial withdrawal in the US. Tesamorelin instead reproduces the complete 44-amino-acid native peptide and adds a stability modification specifically engineered to extend its usable pharmacological life, targeting a different clinical problem: sustained, once-daily reduction of pathological visceral fat accumulation in a defined adult population rather than diagnostic pituitary-reserve testing in children.

Tesamorelin (developed under the laboratory code TH9507) was created by Theratechnologies, a Montreal-based biopharmaceutical company, and progressed through a substantial phase III programme in adults living with HIV who had developed excess abdominal visceral fat as a consequence of antiretroviral therapy and the HIV-lipodystrophy syndrome. The pivotal trials demonstrated selective, statistically robust reductions in visceral adipose tissue without corresponding loss of subcutaneous fat, alongside favourable effects on triglycerides. This body of evidence supported FDA approval in November 2010 under the brand name Egrifta, specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

This approval is the central fact that separates tesamorelin from every other GHRH analogue covered on this site. Sermorelin, CJC-1295 and related compounds remain unlicensed research or historically-licensed-but-withdrawn compounds; tesamorelin is a current, actively marketed prescription medicine in the United States with fifteen years of post-marketing safety surveillance behind it, albeit for a narrow, specific indication rather than for longevity or healthy-ageing use. This page summarises the mechanism, regulatory history, published trial data and UK regulatory framing relevant to that distinction.

Mechanism of action

Tesamorelin binds and activates the GHRH receptor on anterior pituitary somatotrophs, the same Gs-coupled, adenylate-cyclase-linked receptor targeted by sermorelin and by endogenous hypothalamic GHRH. Receptor activation triggers pulsatile release of growth hormone from pituitary secretory stores, reproducing the physiological signalling pathway rather than substituting for it. As a full-length 44-amino-acid molecule with a stabilising N-terminal modification, tesamorelin achieves more consistent receptor engagement across a once-daily dosing interval than short-acting fragments, without converting pulsatile release into the sustained, feedback-independent elevation seen with drug-affinity-complex-modified compounds such as CJC-1295 with DAC.

GH released in response to tesamorelin drives hepatic and peripheral IGF-1 production through the standard downstream cascade, and — as with all GHRH-receptor agonists — remains subject to physiological negative feedback from circulating IGF-1, GH itself, and hypothalamic somatostatin tone. This feedback preservation is the pharmacological feature shared across the entire GHRH-analogue class and is the principal argument distinguishing GHRH agonism from recombinant human GH administration, which bypasses pituitary regulation entirely and produces sustained supraphysiological GH/IGF-1 levels with no comparable brake.

The feature that differentiates tesamorelin clinically is its disproportionate effect on visceral rather than subcutaneous adipose tissue. Visceral adipocytes carry a higher density of GH receptors and a more GH-sensitive lipolytic response than subcutaneous fat depots, and sustained GH/IGF-1 elevation from tesamorelin selectively mobilises this visceral compartment. In the pivotal HIV-lipodystrophy trials this manifested as visceral adipose tissue (VAT) reductions in the order of 15–18% relative to placebo over 26 weeks, with subcutaneous fat essentially unchanged — a selectivity profile that is unusual among metabolic interventions and is the specific mechanism underlying tesamorelin's licensed indication.

Pharmacokinetically, tesamorelin's DPP-IV-resistant N-terminal modification extends its plasma half-life to roughly 26–38 minutes, longer than unmodified GHRH 1-44 or sermorelin's short window, though still far shorter than DAC-modified CJC-1295. This intermediate half-life, combined with once-daily subcutaneous dosing before bedtime, was designed to approximate the natural GHRH pulse that drives slow-wave-sleep GH secretion while providing enough sustained receptor engagement for a commercially viable, consistent dosing regimen — a pharmacological compromise between the brief action of sermorelin and the multi-day depot behaviour of DAC-modified analogues.

Research history

Tesamorelin was developed by Theratechnologies, a biopharmaceutical company based in Montreal, Quebec, through the 1990s and 2000s as TH9507, a stabilised full-length GHRH analogue engineered specifically for resistance to DPP-IV degradation. The company's clinical programme focused from an early stage on HIV-associated lipodystrophy, a syndrome of abnormal fat redistribution — including pathological visceral fat accumulation — that emerged as a recognised complication of long-term antiretroviral therapy through the 1990s and 2000s.

The pivotal phase III programme, led by Julian Falutz and colleagues and reported in the New England Journal of Medicine in 2007, randomised HIV-infected adults with excess abdominal fat to tesamorelin 2 mg daily or placebo for 26 weeks and demonstrated selective visceral fat reduction with improvements in triglycerides, without significant adverse effects on glycaemic measures. A subsequent pooled analysis with 52-week safety-extension data, published in the Journal of Clinical Endocrinology & Metabolism in 2010, confirmed durability of the visceral-fat effect and characterised the longer-term safety profile that ultimately supported the FDA's approval decision later that year.

Since 2010 approval, off-label and investigator-initiated research interest in tesamorelin has expanded well beyond the licensed lipodystrophy indication. A National Institutes of Health-funded trial by Baker and colleagues examined cognitive effects in older adults, including those with amnestic mild cognitive impairment, reporting favourable executive-function outcomes. Separate investigator-led work examined tesamorelin's effect on hepatic (liver) fat in HIV-associated non-alcoholic fatty liver disease, given that visceral adiposity and hepatic steatosis are mechanistically linked. This broader research programme — cognitive ageing, hepatic fat, body composition — sits outside tesamorelin's licensed indication and has not itself been submitted for additional regulatory approval, but it is the basis for contemporary longevity- and healthy-ageing-adjacent interest in the compound.

Summarised studies